fruquintinib + camrelizumab

Fruquintinib + camrelizumab is a combination therapy consisting of fruquintinib, an oral small-molecule tyrosine kinase inhibitor highly selective for vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR-1/2/3), and camrelizumab, a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1). Fruquintinib inhibits tumor angiogenesis by blocking VEGFR-mediated signaling pathways essential for blood vessel formation in tumors. Camrelizumab acts as an immune checkpoint inhibitor by binding to PD-1 on T cells, thereby enhancing anti-tumor immune responses. This combination is under investigation primarily for the treatment of metastatic colorectal cancer (mCRC), particularly in patients with microsatellite stable (MSS) or proficient mismatch repair (pMMR) tumors who have progressed after standard therapies. Early-phase clinical studies suggest promising efficacy and manageable toxicity profiles[1][3][4].